IDEC is focused on developing improved treatments for autoimmune and inflammatory diseases, such as psoriasis, rheumatoid arthritis, asthma, Crohn’s disease and immune thrombocytopenic purpura (ITP), both on its own and with a trio of corporate partners. Autoimmune disease is the underlying cause of numerous serious, chronic illnesses.
IDEC-131 targets the CD40 ligand on T cells, which interact with antibody-producing B cells. By regulating the interaction between T and B cells, IDEC-131 may reduce excessive antibody production and may help restore a more normal immune response in patients with a variety of autoimmune-related conditions.
Clinical Trial Updates
In July 2001 IDEC initiated a Phase II, multi-center, randomized, placebo-controlled, multiple-dose, dose-ranging study of IDEC-131, a humanized anti-CD154 (anti-CD40L) monoclonal antibody, in patients with Crohn’s disease, an inflammatory bowel disorder of unknown cause. The study will assess safety and clinical activity.
In late January 2001 IDEC launched a multi-center, pilot Phase II clinical trial with IDEC-131. The multiple-dose study will evaluate clinical activity and safety in patients with moderate to severe psoriasis, a T-cell mediated disease.
Also in January 2001 IDEC began a Phase II, multi-center, multiple-dose study to evaluate clinical activity and safety in patients with chronic, refractory immune thromobocytopenic purpura (ITP), a blood disorder characterized by low platelet counts which can pose a significant risk of life-threatening bleeding.
Results from these three trials will not be known until 2002.
Ex-U.S. Marketing Rights
Eisai Co. Ltd. has marketing rights to IDEC-131 in Europe and Asia.